Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Medical Device Regulatory Submissions in 2026: 510(k), De Novo, PMA, eSTAR, and FDA Approval Guide

Explore how FDA medical device submissions work across 510(k), De Novo, PMA, and eSTAR pathways. Learn how classification, predicate strategy, evidence planning, substantial equivalence, and quality documentation can support smoother premarket review and stronger regulatory readiness.
  • Blog, Medical Devices
Medical device premarket submission workflow showing eSTAR submission, predicate device comparison, substantial equivalence, and FDA premarket review.

FDA Rare Disease Shift 2026; New Regulatory Risks Pharma Teams Must Track

The U.S. Food and Drug Administration (FDA) is facing growing attention over how it evaluates Rare Disease Therapies in 2026. Discussions around FDA Advisory Committees (AdComms) and patient-focused decision-making highlight a broader regulatory transformation that may reshape how pharmaceutical companies
  • News
FDA Rare Disease Shift 2026; New Regulatory Risks Pharma Teams Must Track

Good Manufacturing Practices in Malaysia in 2026: NPRA GMP Inspection Guide

Learn how Malaysia GMP guidelines and NPRA GMP inspections align with PIC/S GMP requirements. This guide explains pharmaceutical quality systems, inspection priorities, common findings, CAPA expectations, and practical strategies to improve GMP compliance and inspection readiness.
  • Blog, Quality Management System
NPRA GMP inspection in a pharmaceutical manufacturing Malaysia facility following PIC/S GMP requirements and pharmaceutical quality system standards

FDA Freezes CRL Transparency; What Changes for Pharma Compliance

The FDA has paused the public release of new Complete Response Letters (CRLs) while reviewing a citizen petition that challenges the legal basis of the disclosure program. The decision temporarily interrupts one of the agency’s most significant transparency initiatives and
  • News
FDA Freezes CRL Transparency; What Changes for Pharma Compliance

FDA Transparency Hits a Roadblock; Why Drug Rejection Letters Suddenly Stopped

The U.S. Food and Drug Administration (FDA) has temporarily paused the public release of Complete Response Letters (CRLs). The agency made the decision after an unnamed pharmaceutical company challenged the policy over confidentiality concerns. The move temporarily suspends one of
  • News
FDA Transparency Hits a Roadblock; Why Drug Rejection Letters Suddenly Stopped

EMA Launches Phased Reviews; Why GMP Submission Strategies Must Change

The European Medicines Agency (EMA) has started a phased review of daraxonrasib, an investigational therapy for metastatic pancreatic cancer. However, the biggest story is not the medicine itself. Instead, the review marks one of the first real-world applications of a
  • News
EMA Launches Phased Reviews; Why GMP Submission Strategies Must Change

Regulatory Compliance Consulting in 2026: FDA, EMA, and Regulatory Affairs

Discover how pharmaceutical regulatory consulting helps organizations eliminate common GMP compliance gaps, improve FDA Compliance and EMA Compliance, implement ICH Guidelines, strengthen regulatory strategy, and achieve greater inspection readiness for successful global market authorization.
  • Blog, Quality Management System
Infographic illustrating common GMP inspection gaps, including documentation, CAPA, data integrity, change control, and risk management that support regulatory consulting services, FDA Compliance, EMA Compliance, and ICH Guidelines.

The Role of the EMA in Vaccine Approvals

In response to the COVID-19 pandemic, the European Medicines Agency (EMA) adapted its vaccine approval processes, implementing rolling reviews and enhancing collaboration with health authorities. This post analyzes the EMA's pivotal role in granting conditional marketing authorizations for COVID-19 vaccines
  • GxP, Quality Management System
Close up on vaccine and medical syringe

Medical Device Regulations Comparing Across the Continents

Though a leader in medical device regulation, Europe's MDR presents a hurdle for global manufacturers. This excerpt compares it to the US FDA's 510(k) pathway, highlighting stricter European requirements for data, documentation, and risk management. Understanding these variations is vital
  • MD/IVD Regulations, Medical Devices